Truist downgraded Point Biopharma (PNT) to Hold from Buy with a price target of $12.50, down from $13, after the company announced an all-cash takeover by Eli Lilly (LLY) at $12.50 per share. The analyst notes that the acquisition price is a “good deal” for Point Biopharma, though the firm awaits to understand if the transaction involved a competitive process.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PNT:
- Lantheus program validated by Point Biopharma buyout, says Mizuho
- Point Biopharma downgraded to Neutral from Buy at Guggenheim
- Point Biopharma downgraded to Market Perform from Outperform at William Blair
- Point Biopharma downgraded to Hold from Buy at JonesResearch
- Point Biopharma downgraded to Hold from Buy at Jefferies